陳志濤,王 萍,孫圣斌,張 姮,吳 杰
·論著·
結直腸腺瘤危險因素及幽門螺桿菌感染與腺瘤特征和血清胃泌素水平的相關性研究
陳志濤,王 萍,孫圣斌,張 姮,吳 杰*
背景 幽門螺桿菌(Hp)感染不僅是胃癌的主要致病因素,而且與結直腸腺瘤相關,但在不同種族間的結論不一致。目的 探討結直腸腺瘤患者的危險因素,以及Hp感染與腺瘤特征和血清胃泌素水平的相關性。方法 回顧性收集2011—2015年華中科技大學同濟醫學院附屬武漢市中心醫院收治的結直腸腺瘤患者1 000例為結直腸腺瘤組,同時收集同時期本院通過結腸鏡行結腸癌篩查未見腸道異常者1 500例為對照組。收集兩組患者一般資料,采用14C尿素呼氣試驗檢測Hp感染情況。酶聯免疫吸附試驗法測定血清細胞毒素相關基因A(CagA)蛋白和胃泌素水平。結直腸腺瘤組患者根據Hp感染情況分為Hp感染者(n=623)及非Hp感染者(n=377),Hp感染者根據是否表達CagA蛋白進一步分為CagA蛋白(+)(n=510)和CagA蛋白(-)(n=113)。結直腸腺瘤危險因素采用多因素Logistic回歸分析。結果 結直腸腺瘤組患者Hp感染率較對照組升高〔62.30%(623/1 000)與54.33%(815/1 500),OR=1.39,95%CI(1.18,1.64),P<0.001〕。多因素Logistic回歸分析結果顯示:高脂血癥、結腸癌家族史及Hp感染為結直腸腺瘤的獨立危險因素(P<0.05)。結直腸腺瘤患者Hp感染者與非Hp感染者腺瘤數目、腺瘤蒂部分型、腺瘤病理類型比較,差異均無統計學意義(P>0.05);Hp感染者與非Hp感染者腺瘤大小及腺瘤伴高級別上皮內瘤變發生率比較,差異均有統計學意義(P<0.05)。結直腸腺瘤患者CagA蛋白(+)Hp感染者血清胃泌素水平〔(65.78±9.23)ng/L〕高于CagA蛋白(-)Hp感染者〔(55.04±8.05)ng/L〕和非Hp感染者〔(51.04±4.95)ng/L〕(P<0.05)。結論 高脂血癥、結腸癌家族史及Hp感染為結直腸腺瘤的危險因素,結直腸腺瘤患者CagA蛋白(+)Hp感染者血清胃泌素水平升高。推測CagA蛋白所釋放的促炎因子可能會促進結直腸上皮細胞的增殖,導致CagA蛋白(+)Hp感染人群結直腸上皮細胞增殖活躍、異常增生,從而增加結直腸腺瘤的發生。
結直腸腫瘤;幽門螺桿菌;細胞毒素相關基因A;胃泌素類
陳志濤,王萍,孫圣斌,等.結直腸腺瘤危險因素及幽門螺桿菌感染與腺瘤特征和血清胃泌素水平的相關性研究[J].中國全科醫學,2017,20(2):154-158.[www.chinagp.net]
CHEN Z T,WANG P,SUN S B,et al.Risk factors for colorectal adenomas,association of helicobacter pylori infection with features of colorectal adenomas and serum gastrin levels[J].Chinese General Practice,2017,20(2):154-158.
幽門螺桿菌(Helicobacter pylori,Hp)被國際癌癥研究機構列為胃癌的一類致癌原,是引起散發性胃癌的主要危險因素[1]。細胞毒素相關基因A(cytotoxin-associated gene A,CagA)存在于Hp高毒力菌株中,其表達產物為CagA蛋白,為可溶性蛋白,存在于血清中,是Hp產生致病作用的重要毒力因子之一[2]。并非所有的Hp菌株均表達CagA蛋白,與CagA蛋白(-)Hp菌株相比,CagA蛋白(+)Hp菌株可引起胃黏膜更嚴重的炎性反應,且更能增加胃癌的發病風險[3-4]。然而近年來,不斷有證據表明Hp感染不僅是胃癌的主要致病因素,而且也與胃外的腫瘤有關,研究報道Hp感染亦與結直腸、肝膽及胰腺部位等腫瘤相關[5]。研究發現,Hp感染增加結直腸腺瘤的發病[6-7],亦有部分研究顯示,Hp感染與結直腸腺瘤無明顯相關性[8-9]。結果存在一定爭議。研究發現,Hp感染可導致胃體黏膜萎縮,通過對胃竇G細胞負反饋調節致使血清胃泌素水平升高[10-11]。胃泌素通過刺激生長因子依賴的信號轉導通路從而參與疾病的發生,因此,Hp感染所導致的高胃泌素血癥可能成為導致結直腸腫瘤發病的始動因子。體外實驗表明,高胃泌素水平與結直腸癌發病有關[12-14]。雖然,Hp感染與結直腸癌的相關性研究較多,但其可能的病理生理機制仍未闡明,尤其是結直腸腺瘤。因此,本研究探討結直腸腺瘤的危險因素,以及Hp感染與腺瘤特征和血清胃泌素水平的相關性,旨在為預防結直腸腺瘤癌變及Hp的根除指征提供理論依據。
本研究背景和創新點:
越來越多的研究提示幽門螺桿菌(Hp)感染不僅是胃癌的主要致病因素,而且與結直腸腺瘤相關,但不同種族間的結論存在一定爭議,且其可能的病理生理機制仍未闡述。因此,本研究探討結直腸腺瘤的危險因素及Hp感染與腺瘤特征和血清胃泌素水平的相關性,旨在為結直腸腺瘤的治療、預防及Hp的根除指征提供理論依據。
1.1 研究對象 回顧性收集2011—2015年華中科技大學同濟醫學院附屬武漢市中心醫院收治的結直腸腺瘤患者1 000例為結直腸腺瘤組,均經臨床、實驗室、放射學、內鏡及組織病理學檢查綜合診斷[15]。每例結直腸腺瘤患者的臨床資料均登記注冊,有完整的結腸鏡和病理學診斷資料。同時收集同時期本院通過結腸鏡行結腸癌篩查未見腸道異常者1 500例為對照組。所有受試者于本院接受胃鏡檢查診斷為慢性胃炎,慢性胃炎診斷標準參考2004年中華醫學會消化內鏡學分會《慢性胃炎的內鏡分型分級標準及治療的試行意見》[16]。排除標準:(1)年齡<18歲者;(2)妊娠期婦女;(3)自身免疫性疾病者;(4)曾行Hp根除治療者;(5)近4周服用過質子泵抑制劑、H2受體拮抗劑、抗生素及糖皮質激素者;(6)有其他部位惡性腫瘤病史者;(7)有胃腸道手術史者。受試者均簽署知情同意書,該研究項目獲華中科技大學同濟醫學院附屬武漢市中心醫院倫理委員會批準。
1.2 方法
1.2.1 一般資料 收集兩組患者的一般資料,包括性別、年齡、吸煙、飲酒、體質指數、既往糖尿病、高血壓、高脂血癥病史、結腸癌家族史。吸煙定義為:每天至少吸煙1只,連續吸煙1年以上,長期吸煙但戒煙短于半年者;飲酒定義為:每天至少飲酒50 g,連續飲酒1年以上,或戒酒未超過半年者。
1.2.2 Hp檢測 Hp感染參照我國2012年《第四次全國幽門螺桿菌感染處理共識報告》定義為:14C尿素呼氣試驗陽性定義為Hp感染陽性。14C尿素呼氣試驗檢測數值≥100 dpm/mmol為陽性,<100 dpm/mmol為陰性[17]。
1.2.3 組織病理學評估 結直腸腺瘤經內鏡下切除后樣本常規處理、蘇木素-伊紅染色。參照世界衛生組織標準[15]評估所有切除樣本發育不良的級別以及絨毛結構等情況。結直腸腺瘤蒂部分型分為有蒂和無蒂兩種類型[18]。
1.2.4 血清采集 采集結直腸腺瘤組和對照組無抗凝外周靜脈血5 ml,在3 h內,1 000×g離心10 min(室溫),收集血清。于-80 ℃冰箱保存待檢。
1.2.5 血清CagA蛋白檢測 采用酶聯免疫吸附試驗(ELISA)試劑盒(CSB-E09170h, CUSABIO)檢測結直腸腺瘤組和對照組血清CagA蛋白含量,具體步驟參照試劑盒說明書。采用酶標儀在波長450 nm處檢測樣本吸光度值(optical density,OD值)。OD值樣本/OD值陰性對照≥2.1為CagA蛋白表達陽性,OD值樣本/OD值陰性對照< 2.1為CagA蛋白表達陰性。
1.2.6 血清胃泌素水平檢測 采用ELISA試劑盒(CSB-E09166h,CUSABIO)檢測結直腸腺瘤組和對照組血清胃泌素水平(ng/L),具體步驟參照試劑盒說明書。

2.1 對照組與結直腸腺瘤組患者一般資料比較 對照組與結直腸腺瘤組患者性別、年齡、吸煙率、飲酒率、體質指數、既往糖尿病、高血壓病史比較,差異均無統計學意義(P>0.05);兩組患者既往高脂血癥病史、結腸癌家族史比較,差異均有統計學意義(P<0.05,見表1)。
2.2 對照組與結直腸腺瘤組患者Hp感染率比較 對照組患者Hp感染率為54.33%(815/1 500),結直腸腺瘤組患者Hp感染率為62.30%(623/1 000),結直腸腺瘤組患者Hp感染率較對照組升高,差異有統計學意義〔OR=1.39,95%CI(1.18,1.64),χ2=15.585,P<0.001〕。
2.3 結直腸腺瘤危險因素的多因素Logistic回歸分析 以性別(賦值:男=1,女=0)、年齡(連續變量)、吸煙(賦值:有=1,無=0)、飲酒(賦值:有=1,無=0)、體質指數(連續變量)、糖尿病(賦值:有=1,無=0)、高血壓(賦值:有=1,無=0)、高脂血癥(賦值:有=1,無=0)、結腸癌家族史(賦值:有=1,無=0)、Hp感染(賦值:有=1,無=0)為自變量,以結直腸腺瘤(賦值:是=1,否=0)為因變量,采用逐步法進行多因素Logistic回歸分析,結果顯示:高脂血癥、結腸癌家族史及Hp感染為結直腸腺瘤的獨立危險因素(P<0.05,見表2)。
表2 結直腸腺瘤危險因素的多因素Logistic回歸分析
Table2MultivariateLogisticregressionanalysisontheriskfactorsforcolorectaladenomas

變量βSEWaldχ2值P值OR值(95%CI)高脂血癥0641034222370024138(118,503)結腸癌家族史0863102445420015153(121,325)Hp感染0574089735640032117(113,427)
注:Hp=幽門螺桿菌
2.4 結直腸腺瘤患者Hp感染者與非Hp感染者腺瘤特征比較 結直腸腺瘤患者Hp感染者623例,非Hp感染者377例,結直腸腺瘤患者Hp感染者與非Hp感染者腺瘤數目、腺瘤蒂部分型、腺瘤病理類型比較,差異均無統計學意義(P>0.05);Hp感染者與非Hp感染者腺瘤大小及腺瘤伴高級別上皮內瘤變發生率比較,差異均有統計學意義(P<0.05,見表3)。
2.5 CagA蛋白表達對血清胃泌素水平的影響 結直腸腺瘤患者Hp感染者根據是否表達CagA蛋白進一步分為CagA蛋白(+)(n=510)和CagA蛋白(-)(n=113)。結直腸腺瘤患者CagA蛋白(+)Hp感染者血清胃泌素水平〔(65.78±9.23)pg/ml〕高于CagA蛋白(-)Hp感染者〔(55.04±8.05) pg/ml〕和非Hp感染者〔(51.04±4.95) pg/ml〕,差異有統計學有意義(q=-11.234,P=0.013;q=-9.265,P=0.004);結直腸腺瘤患者CagA蛋白(-)Hp感染者血清胃泌素水平與非Hp感染者比較,差異無統計學意義(q=4.167,P=0.742)。

表1 對照組與結直腸腺瘤組患者一般資料比較
注:a為t值

表3 結直腸腺瘤患者Hp感染者與非Hp感染者腺瘤特征比較〔n(%)〕
隨著生活方式的不斷變化、飲食結構的調整以及各種微生物的感染,結直腸癌的發病率逐年上升,嚴重影響患者的身心健康[19-21]。腺瘤-癌序貫學說已被廣泛關注,結直腸腺瘤是結直腸癌的主要癌前病變[22-23]。因此,調查結直腸腺瘤發生的危險因素對早期預防結直腸癌、降低結直腸癌的發生率有積極的臨床意義。本研究結果表明,結直腸腺瘤組患者Hp感染率明顯高于對照組,Hp感染是結直腸腺瘤的獨立危險因素。且結直腸腺瘤患者Hp感染者與非Hp感染者腺瘤大小及腺瘤伴高級別上皮內瘤變發生率有差異。結直腸腺瘤患者Hp感染者發生>2 cm腺瘤及發生腺瘤伴高級別上皮內瘤變的概率明顯高于非Hp感染者。這些發現均提示Hp感染陽性的人群罹患結直腸腺瘤的風險增高。BRIM等[6]發現,非裔美國人群中結直腸腺瘤患者Hp感染率明顯高于健康對照者。SONNENBERG等[8]研究報道,Hp感染影響結直腸腺瘤的大小及數目。雖然PATEL等[24]研究發現,拉美裔人群中Hp感染與結直腸腺瘤無明顯相關性,然而,最近一項東亞人群的Meta分析顯示Hp感染增加結直腸腺瘤的發生[7]。出現這些分歧的可能原因與種族差異、遺傳、環境因素及樣本量大小不同有關。
Hp感染與結直腸腺瘤相關的病理生理機制不明,有研究報道高胃泌素血癥與結直腸腫瘤相關[12,25-26]。Hp感染是否通過增加血清胃泌素的水平從而參與結直腸腺瘤的發病。因此,本研究進一步檢測了結直腸腺瘤患者血清胃泌素水平,結果顯示,結直腸腺瘤患者CagA蛋白(+)Hp感染者血清胃泌素水平高于CagA蛋白(-)Hp感染者和非Hp感染者,結直腸腺瘤患者CagA蛋白(-)Hp感染者血清胃泌素水平與非Hp感染者比較無差異。研究顯示,與CagA蛋白(-)Hp菌株比較,CagA蛋白(+)Hp菌株所導致的炎性反應更強烈,且罹患胃癌的風險更高[4]。PEEK等[27]通過胃黏膜活檢標本,采用流式細胞技術分析細胞凋亡,采用免疫組織化學技術檢測胃黏膜上皮細胞增殖指數,發現CagA蛋白(+)Hp感染患者胃黏膜上皮細胞增殖指數明顯高于CagA蛋白(-)Hp感染患者。
綜上所述,Hp感染是結直腸腺瘤發生的獨立危險因素,且Hp感染影響結直腸腺瘤的大小及腺瘤伴高級別上皮內瘤變的發生。CagA蛋白(+)Hp感染結直腸腺瘤患者血清胃泌素水平明顯升高。推測CagA蛋白所釋放的促炎因子可能會促進結直腸上皮細胞的增殖,導致CagA蛋白(+)Hp感染人群結直腸上皮細胞增殖活躍、異常增生,從而導致結直腸腺瘤的發生。但其具體的病理生理機制有待后續進一步研究。
至謝:感謝武漢市中心醫院消化內科全體醫護人員對本課題的支持!
作者貢獻:陳志濤、吳杰進行文章的構思與設計、論文的修訂,負責文章的質量控制及審校;陳志濤、張姮進行研究的實施與可行性分析、數據整理;王萍、孫圣斌進行數據收集、結果的分析與解釋;陳志濤進行統計學處理、撰寫論文;吳杰對文章整體負責,監督管理。
本文無利益沖突。
[1]IARC monographs on the evaluation of carcinogenic risks to humans.Vol.61.Schistosomes,liver flukes and Helicobacter pylori[M].Lyon:IARC,1994:177-240.
[2]WEN S,MOSS S F.Helicobacter pylori virulence factors in gastric carcinogenesis[J].Cancer Lett,2009,282(1):1-8.
[3]BACKERT S,TEGTMEYER N,SELBACH M.The versatility of Helicobacter pylori CagA effector protein functions:the master key hypothesis[J].Helicobacter,2010,15(3):163-176.
[4]PARSONNET J,FRIEDMAN G D,ORENTREICH N,et al.Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection[J].Gut,1997,40(3):297-301.
[5]VENERITO M,SELGRAD M,MALFERTHEINER P.Helicobacter pylori:gastric cancer and extragastric malignancies - clinical aspects[J].Helicobacter,2013,18(Suppl 1):39-43.
[6]BRIM H,ZAHAF M,LAIYEMO A O,et al.Gastric Helicobacter pylori infection associates with an increased risk of colorectal polyps in African Americans[J].BMC Cancer,2014,14:296.
[7]GUO Y,LI H Y.Association between Helicobacter pylori infection and colorectal neoplasm risk:a meta-analysis based on East Asian population[J].J Cancer Res Ther,2014,10(Suppl):263-266.
[8]SONNENBERG A,GENTA R M.Helicobacter pylori is a risk factor for colonic neoplasms[J].Am J Gastroenterol,2013,108(2):208-215.
[9]PAPASTERGIOU V,KARATAPANIS S,GEORGOPOULOS S D.Helicobacter pylori and colorectal neoplasia:is there a causal link? [J].World J Gastroenterol,2016,22(2):649-658.
[10]CHEN X Z,SCH?TTKER B,CASTRO F A,et al.Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic,pancreatic and gastric cancer:a ten-year follow-up of the ESTHER cohort study[J].Oncotarget,2016,7(13):17182-17193.
[11]WATSON S A,GRABOWSKA A M,EL-ZAATARI M,et al.Gastrin-active participant or bystander in gastric carcinogenesis? [J].Nat Rev Cancer,2006,6(12):936-946.
[12]WESTWOOD D A,PATEL O,BALDWIN G S.Gastrin mediates resistance to hypoxia-induced cell death in xenografts of the human colorectal cancer cell line LoVo[J].Biochim Biophys Acta,2014,1843(11):2471-2480.
[13]ROBERTSON D J,SANDLER R S,AHNEN D J,et al.Gastrin,Helicobacter pylori,and colorectal adenomas[J].Clin Gastroenterol Hepatol,2009,7(2):163-167.
[14]GEORGOPOULOS S D,POLYMEROS D,TRIANTAFYLLOU K,et al.Hypergastrinemia is associated with increased risk of distal colon adenomas[J].Digestion,2006,74(1):42-46.
[15]HAMILTON S R,VOGELSTEIN B,KUDO S.World Health Organization classification of tumours:pathology and genetics of tumours of the digestive system[M].Lyon:IARC,2000.
[16]中華醫學會消化內鏡學分會.慢性胃炎的內鏡分型分級標準及治療的試行意見[J].中華消化內鏡雜志,2004,21(2):77-78. Chinese Society of Digestive Endoscopy.Trial on treatment and typing or grading chronic gastritis under endoscopies[J].Chinese Journal of Digestive Endoscopy,2004,21(2):77-78.
[17]中華醫學會消化病學分會幽門螺桿菌學組/全國幽門螺桿菌研究協作組,劉文忠,謝勇,等.第四次全國幽門螺桿菌感染處理共識報告[J].中華消化雜志,2012,32(10):655-661. Chinese Society of Gastroenterology Helicobacter Pylori Group/China Research Group of Helicobacter Pylori,LIU W Z,XIE Y,et al.The 4th National Consensus on helicobacter pylori infection treatment[J].Chinese Journal of Digestion,2012,32(10):655-661.DOI:10.3760/cma.j.issn.0254-1432.2012.10.002.
[18]SCHACHSCHAL G,MAYR M,TRESZL A,et al.Endoscopic versus histological characterization of polyps during screening colonoscopy[J].Gut,2014,63(3):458-465.
[19]陳紅,任淑華,龐紅梅,等.埃克替尼與卡培他濱治療老年結直腸癌療效比較[J].中國全科醫學,2013,16(33):3960-3962. CHEN H,REN S H,PANG H M,et al.Clinic research on icotinib and capecitabine in the treatment of senile advanced colorectal cancer[J].Chinese General Practice,2013,16(33):3960-3962.
[20]ZHENG Z X,ZHENG R S,ZHANG S W,et al.Colorectal cancer incidence and mortality in China,2010[J].Asian Pac J Cancer Prev,2014,15(19):8455-8860.
[21]SUNG J J,LAU J Y,GOH K L,et al.Increasing incidence of colorectal cancer in Asia:implications for screening[J].Lancet Oncol,2005,6(11):871-876.
[22]WONG M C,CHING J Y,CHIU H M,et al.Risk of colorectal neoplasia in individuals with self-reported family history:a prospective colonoscopy study from 16 Asia-Pacific Regions[J].Am J Gastroenterol,2016,111(11):1621-1629.
[23]陳冬妹,肖文,張滿芬.葉酸對結直腸腺瘤復發干預作用的隨訪研究[J].中國全科醫學, 2012,15(2):496-497. CHEN D M,XIAO W,ZHANG M F.Interventional effects of folic acid on recurrence of colorectal adenoma: follow-up study[J].Chinese General Practice,2012,15(2):496-497.
[24]PATEL S,LIPKA S,SHEN H,et al.The association of H.pylori and colorectal adenoma:does it exist in the US Hispanic population? [J].J Gastrointest Oncol,2014,5(6):463-468.
[25]PATERSON A C,MACRAE F A,PIZZEY C,et al.Circulating gastrin concentrations in patients at increased risk of developing colorectal carcinoma[J].J Gastroenterol Hepatol,2014,29(3):480-486.
[26]HAN Y M,PARK J M,PARK S H,et al.Gastrin promotes intestinal polyposis through cholecystokinin-B receptor-mediated proliferative signaling and fostering tumor microenvironment[J].J Physiol Pharmacol,2013,64(4):429-437.
[27]PEEK R M Jr,MOSS S F,THAM K T,et al.Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis[J].J Natl Cancer Inst,1997,89(12):863-868.
(本文編輯:陳素芳)
Risk Factors for Colorectal Adenomas,Association of Helicobacter Pylori Infection with Features of Colorectal Adenomas and Serum Gastrin Levels
CHENZhi-tao,WANGPing,SUNSheng-bin,ZHANGHeng,WUJie*
DepartmentofGastroenterology,theCentralHospitalofWuhan,TongjiMedicalCollege,HuazhongUniversityofScienceandTechnology,KeyLaboratoryforMolecularDiagnosisofHubeiProvince,ClinicalResearchCenterforIntestinal&ColorectalDiseasesofHubeiProvince,Wuhan430014,China
*Correspondingauthor:WUJie,Professor;E-mail:wujie_20120803@163.com
Background Helicobacter pylori(Hp) infection is not only a major risk factor for gastric cancer but it is also related to colorectal adenomas(CAs),but there are still some contradictory data in different populations.Objective To investigate the risk factors for CAs,and the correlation of Hp infection with features of CAs and serum gastrin levels.Methods From 2011 to 2015,in the Central Hospital of Wuhan,Tongji Medical College,Huazhong University of Science and Technology,1 000 consecutive admitted CAs patients were selected as the CAs group,and other 1 500 physical examinees with normal manifestations showed by colonoscopy for colorectal cancer screening were selected as the control group.The general data of both groups were collected.Hp infection was determined by14C urea breath tests.Serum cytotoxin-associated gene A(CagA) protein and gastrin levels were measured by ELISA.The patients with CAs were divided into Hp-infected subgroup(n=623) and non-Hp-infected subgroup(n=377) based on whether they infected with Hp,then the Hp-infected subgroup was further assigned to CagA-positive patients(n=510) and CagA-negative patients(n=113) in accordance with whether the Hp strains expressed the CagA.The risk factors of CAs were estimated by multivariate Logistic regression.Results Hp infection was more frequently detected in patients with CAs compared to the controls〔62.30%(623/1 000)vs.54.33%(815/1 500),OR=1.39,95%CI(1.18,1.64),P<0.001〕.The results of multivariate Logistic regression showed that hyperlipidemia,family history of colorectal cancer and Hp infection were independent risk factors for the development of CAs(P<0.05).In CAs patients,there were no associations between Hp infection and adenoma number,presence of a pedicle and the pathological type(P>0.05).Hp infection was associated with the diameter of adenomas and adenomas presenting with high grade intraepithelial neoplasia in CAs patients(allP<0.05).In CAs patients,serum gastrin level was higher in that infected with Hp and positive CagA〔(65.78±9.23)ng/L〕 than in that infected with Hp and negative CagA〔(55.04±8.05)ng/L〕 and than in that without Hp infection〔(51.04±4.95)ng/L〕(P<0.05).Conclusion Hyperlipidemia,family history of colorectal cancer and Hp infection are the risk factors for the development of CAs.Hp-infected patients harboring CagA-positive strains have higher serum gastrin level and stronger ability of colorectal epithelial proliferation compared to CagA-negative strains in CAs patients.We speculate that the pro-inflammatory cytokines released by the CagA may promote colorectal epithelial cell proliferation,which would increase the occurrence of colorectal adenomas.
Colorectal neoplasms;Helicobacter pylori;Cytotoxin-associated gene A;Gastrins
國家自然科學基金青年基金資助項目(81400578);國家教育部博士點基金資助項目(20130142120096);武漢市衛生局項目(WX13A07,WX13B03)
R 735.37
A
10.3969/j.issn.1007-9572.2017.02.007
2016-05-16;
2016-11-11)
430014湖北省武漢市,華中科技大學同濟醫學院附屬武漢市中心醫院消化內科,分子診斷湖北省重點實驗室,湖北省腸病醫學臨床研究中心
*通信作者:吳杰,教授;E-mail:wujie_20120803@163.com